Latest Market Developments in Urea Cycle Disorders Treatment Industry: Forecast 2025–2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Industry Valuation for the Urea Cycle Disorders Treatment Sector?
In recent times, there has been consistent growth in the market size of urea cycle disorders treatment. The market is projected to expand from $1.33 billion in 2024 to $1.37 billion in 2025, with a compound annual growth rate (CAGR) of 2.9%. The market’s growth during the previous period was driven by factors such as increased awareness and education, advancements in newborn screening techniques, the creation of patient support networks, and the establishment of care standards guidelines.
The market size for treating urea cycle disorders is predicted to undergo consistent expansion over the approaching years. It’s estimated that by 2029 it will reach “$1.62 billion, with a compound annual growth rate (CAGR) of 4.2%. Contributing factors to this growth during the forecast period include progress in enzyme replacement therapy, wider newborn screening initiatives, heightened collaboration in research, the extension of therapeutic alternatives, and advancements in telemedicine and remote care. Future trends that are expected to be prevalent during the forecast period are refinement in gene editing techniques, awareness and advocacy drives, breakthroughs in regenerative medicine, long-term effectiveness and security studies, and tailored nutritional therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12237&type=smp
What Forces Are Driving The Growth Of The Urea Cycle Disorders Treatment Market?
The growing number of urea cycle disorder cases are anticipated to boost the expansion of the treatment market for those disorders. Urea cycle disorder is an innate metabolic disorder which occurs due to a defect in one of the enzymes or transporter molecules required to eliminate ammonia from the body by the liver. This increase is motivated by genetic disorders. Once a urea cycle disorder (UCD), due to ammonia accumulation, is recognized, a personalized treatment plan combining dietary modification, medication, and surveillance can be executed to handle and diminish its adverse effects. For instance, StatPearls Publishing LLC, a medical education library based in the US, revealed in April 2023 that the incidence of urea cycle disorders due to ornithine transcarbamylase deficiency was 1 in 140,000 people. Additionally, in September 2022, Lecturio, a German digital medical education platform, stated that approximately 1 in every 35,000 global live births and 1 in 8,200 live births in the US experience urea cycle disorders (UCDs), resulting in about 113 new cases annually in the US and roughly 149 in Europe. Consequently, the escalating prevalence of urea cycle disorders is promoting the expansion of the urea cycle disorders treatment market.
The urea cycle disorders treatment market covered in this report is segmented –
1) By Treatment: Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, Other Treatments
2) By Enzyme Deficiency: Ornithine Transcarbamylase (OTC), Argininosuccinate Synthetase (AS), Arginase (AG), Argininosuccinate Lyase (AL), Carbamoyl Phosphate Synthase (CPS1)
3) By Route of Administration: Oral, Injectables
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Amino Acid Supplements: Arginine Supplements, Citrulline Supplements, Other Essential Amino Acids
2) By Sodium Phenylbutyrate: Powder Form, Tablet Form
3) By Glycerol Phenylbutyrate: Oral Solutions, Other Forms
4) By Sodium Benzoate: Intravenous Solutions, Oral Formulations
5) By Other Treatments: Liver Transplantation, Dietary Modifications, Enzyme Replacement Therapy, Other Supportive Therapies
What Are The Leading Trends And Opportunities In The Urea Cycle Disorders Treatment Sector?
Product innovation has been identified as a significant trend that is increasingly popular in the urea cycle disorder treatment market. Major players in this market are focusing on the development of innovative products to solidify their market presence. For instance, in September 2022, U.S. pharmaceutical company Medunik USA launched a distinctive and flavor-concealing formulation of sodium phenylbutyrate (NaPB) called Pheburane oral pellets. These are intended for the enduring management of specific urea cycle disorders. The product is a prescription medication used with a special diet to handle urea cycle disorders (UCDs) in adults and children related to deficiencies in carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinate synthetase (AS). The dosage is measured using a reusable, calibrated spoon that is included in the package; a unique feature of this product is that it doesn’t need to be mixed or ingested orally like other NaPB forms. Pheburane can be enjoyed with a meal or snack, or sprinkled onto a spoonful of apple sauce or carrot puree, accompanied by water, fruit juice, or protein-free infant formula.
Which Companies Currently Dominate The Competitive Landscape In The Urea Cycle Disorders Treatment Industry?
Major companies operating in the urea cycle disorders treatment market include Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding (Lucane Pharma SA), Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics, Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc., Abbott Laboratories, Mead Johnson & Company, LLC, Horizon Therapeutics Plc, Nestlé S.A., Danone S.A., Biophone, Relief Therapeutics Holding AG, TheraTriage, Genomatica, Protalix BioTherapeutics, Erytech Pharma, 4D Pharma, Synlogic, Amicus Therapeutics, Sobi, Astellas Pharma Inc., Chiesi Farmaceutici S.p.A., Medpace Holdings, Inc., Celerion, and PTC Therapeutics
Which Geographic Regions Are Driving Demand In The Urea Cycle Disorders Treatment Market?
North America was the largest region in the urea cycle disorders treatment market in 2024. The regions covered in the urea cycle disorders treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12237&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
